Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Hu, Xi-Chun, Prof, Zhang, Jian, MD, Xu, Bing-He, Prof, Cai, Li, Prof, Ragaz, Joseph, Prof, Wang, Zhong-Hua, MD, Wang, Bi-Yun, MD, Teng, Yue-E, Prof, Tong, Zhong-Sheng, Prof, Pan, Yue-Yin, Prof, Yin, Yong-Mei, Prof, Wu, Chang-Ping, Prof, Jiang, Ze-Fei, Prof, Wang, Xiao-Jia, Prof, Lou, Gu-Yin, MD, Liu, Dong-Geng, MD, Feng, Ji-Feng, Prof, Luo, Jian-Feng, PhD, Sun, Kang, PhD, Gu, Ya-Jia, Prof, Wu, Jiong, Prof, Shao, Zhi-Min, Prof
Published in The lancet oncology (01.04.2015)
Published in The lancet oncology (01.04.2015)
Get full text
Journal Article